|
William W. Howard, Ph.D., MBA
President & CEO
Dr. William W. Howard has thirty years of pharmaceutical experience ranging from laboratory research, to the roll out of sales forces in Europe, to the development of new Rx and OTC products. Howard has worked to develop new products in many categories of prescription drugs including COPD, Cough, Smoking Cessation, Cholesterol Reduction, Anti-Ulcer, Anti-Arthritic and Migraine therapy.
He began his pharmaceutical career with research on drugs of abuse. Following a stint of teaching at Dartmouth College and a post-doctoral at Northwestern, he entered the pharmaceutical industry with Miles Labs (now Bayer) and then moved to Parke-Davis as head of Marketing Management Science. He then founded SDM, Inc. a highly successful global consulting firm. Dr. Howard became involved with Adams in 2001 when the first approval letter for Mucinex® was received and he was asked to help with the unexpected OTC status of the product. He continued as a consultant for Adams until 2004 when he joined the company and later became Senior Vice President of New Products and Business Development.
As Sr. VP, he managed all new product development initiatives and all corporate M&A, business development and licensing activity for the company. In addition, he was responsible for managing the development of new intellectual property on a global basis. Dr. Howard was a member of the Business Operations Team (BOT) and was the key driver of the development of the strategic plan employed by Adams. He played a critical role in the initial contact with Reckitt-Benckiser.
William Howard received a Bachelor's and Master's degree from Cleveland State University and a Ph.D. in Experimental Psychology and Statistics from the University of New Mexico. He did post-doctoral work in epidemiology at the Center for Health Services at Northwestern University where he did research on infant mortality. He holds an MBA from Frederick Taylor University.
|
|
Russell F. Somma, Ph.D.
Senior VP, New Products and Commercial Development
 Russell Somma is an industry veteran with over 25 years of product development experience, primarily at Ciba-Geigy then at Novartis. At Novartis he held a series of positions in product development and manufacturing which culminated in his position as Director of Novel Oral Solid Dosage Forms. His most recent position was President of Somma Tech a consulting firm focused on helping clients meet the manufacturing and quality control requirements for FDA new product approvals. He has also recently assisted some high profile clients in over coming FDA Consent Decrees that required total cessation of all manufacturing operations. With Dr. Somma’s help, several have resumed full production operations, obviously a very valuable service.
Over the span of his career, Dr. Somma has been involved with every phase of product development from bench top formulation and pilot scale manufacture ring to the establishment of full commercial scale operations. Multi-particulate systems are a particular expertise for Somma.
He has been involved in the development and approval of over 25 NDAs so has considerable experience working with the FDA. Indeed, he received a “Special Recognition Award” from Janet Woodcock, MD of FDA for his work in developing the SUPAC-IR Equipment Guidance. Further, he was awarded a “Golden Hammer” by then VP Al Gore for his efforts to reduce red tape and help improve through put at FDA in the area of manufacturing validation.
Dr. Somma has more than 30 publications and presentations in the area of manufacturing and quality control. He is Chairman of the International Society of Pharmaceutical Engineers (ISPE) Quality and Life Cycle Committee. He is also a member of the New Jersey Pharmaceutical Association for Science and Technology.
He receivd his BS, MS and Ph.D. in Pharmaceutical Science from Rutgers University. He is a registered pharmacacist, as well.
|
|
|
|
|
|
